Skip to Content
Merck
All Photos(2)

Documents

O9512

Sigma-Aldrich

Oxaliplatin

powder

Synonym(s):

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C8H14N2O4Pt
CAS Number:
61825-94-3
Molecular Weight:
397.29
MDL number:
MFCD00866327
UNSPSC Code:
12352200
PubChem Substance ID:
329818942
NACRES:
NA.77

form

powder

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Looking for similar products? Visit Product Comparison Guide

Application

Oxaliplatin has been used:
  • as a chemotherapeutic agent in colon rectal adenocarcinoma SW480 cells by cell viability assay
  • for monitoring cell survival in hepatocellular carcinoma HepG2 and HepG2/R cells by MTT assay
  • to determine the growth inhibitory effect on human breast adenocarcinoma MDA-MB-231 cells

Biochem/physiol Actions

Oxaliplatin a platinum analogue, causes DNA damage and cell death by binding to DNA and forming inter and intrastrand crosslinks preventing replication and transcription. Oxaliplatin is an anti-tumor agent with activity against colorectal cancer; cytotoxicity follows the formation of adducts with DNA. Oxaliplatin is an approved drug for treating colorectal cancer. It is an active ingredient in FOLFOX (Folinic acid:5-FU:oxaliplatin in the ratio 1:10:1 of micromolar concentrations respectively). Oxaliplatin causes both acute and chronic neurotoxicity in patients in a dose dependent manner and is reversible either by reducing or stopping the drug.

Features and Benefits

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazardCorrosion
GHS08,GHS05

Signal Word

Danger

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma
Qin Y, et al.
Molecular Medicine Reports, 9(3), 877-881 (2014)
Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study
Votanopoulos KI, et al.
Annals of Surgical Oncology, 1-9 (2018)
Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue
Jamieson SMF, et al.
Molecular Pain, 5(1), 66-66 (2009)
Expression of an oncogenic BARD1 splice variant impairs homologous recombination and predicts response to PARP-1 inhibitor therapy in colon cancer
Ozden O, et al.
Scientific Reports, 6, 26273-26273 (2016)
Bernard Nordlinger et al.
The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)
Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service